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Abstract Niemann–Pick disease type C (NP-C) is a rare
multisystemic lysosomal disorder which, albeit treatable, is
still starkly underdiagnosed. As NP-C features early onset
ataxia (EOA) in 85–90 % of cases, EOA presents a promising
target group for undiagnosed NP-C patients. Here, we asses-
sed the ability of the previously established NP-C suspicion
index (SI) and a novel abbreviated ‘2/3 SI’ tool for rapid
appraisal of suspected NP-C in unexplained EOA. This was a
retrospective observational study comparing ‘NP-C EOA’
cases (EOA patients with confirmed NP-C) with non-NP-C
EOA controls (EOA patients negative for NP-C gene muta-
tions). NP-C risk prediction scores (RPS) from both the
original and 2/3 SIs were calculated and their discriminatory
performance evaluated. Among 133 patients (47 NP-C EOA
cases; 86 non-NP-C EOA controls), moderate (40–69 points)
and high (C70 points) RPS were common based on original SI
assessments in non-NP-C EOA controls [16 (19 %) and 8
(9 %), respectively], but scores C70 points were far more
frequent [46 (98 %)] among NP-C EOA cases. RPS cut-off
values provided 98 % sensitivity and 91 % specificity for NP-
C at 70-point cut-off, and ROC analysis revealed an AUC of
0.982. Using the 2/3 SI, 90 % of NP-C EOA cases had scores
of 2 or 3, and RPS analysis showed an AUC of 0.961. In
conclusion, the NP-C SI and the new, quick-to-apply 2/3 SI
distinguished well between NP-C and non-NP-C patients,
even in EOA populations with high background levels of
broadly NPC-compatible multisystemic disease features.
While the original SI showed the greatest sensitivity, both
tools reliably aided identification of patients with unexplained
EOA who warranted further investigation for NP-C.
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Introduction
Early onset ataxias (EOAs) present a highly heterogeneous
group of degenerative and metabolic diseases, predomi-
nantly caused by recessive mutations in genes with pleio-
tropic, multisystemic manifestations [8]. A genetic
diagnosis can be found in approximately 55 % of cases in
European cohorts [2], and in up to 66 % cases in non-
European cohorts with high consanguinity [5].
The range of ataxia disorders with identified genetic and
phenotypic heterogeneity has been expanding rapidly in
recent years, complicating and prolonging the diagnostic
process in patients presenting with unclear EOA [8].
However, given the stark absence of therapies in this dis-
ease group, confirming a diagnosis is particularly important
in cases where there is an evidence-based drug treatment
available that can treat the underlying disease.
Niemann-Pick disease type C (NP-C) is a rare autosomal
recessive lysosomal lipid storage disorder featuring a wide
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variety of visceral, neurological and psychiatric manifes-
tations [13, 16], with EOA as a cardinal feature: 85–90 %
of all NP-C cases present with EOA [10, 13]. An effective
disease-modifying drug treatment for this condition is
available [1, 9]. However, a large proportion of adult NP-C
patients still remain undiagnosed [14], which emphasises
the need for easy-to-apply clinical tools that can help
identify treatable patients among those with as yet unex-
plained EOA. In a previous study, targeted high-throughput
genetic screening identified NP-C diagnoses in a total of
6/204 (2.9 %) consecutive EOA patients [12]. A clinical
and laboratory diagnostic study in 24 patients with both
EOA and pre-senile cognitive decline resulted in NP-C
diagnoses in four patients (17 %) [10]. Such findings
indicate that the clinical EOA population is substantially
enriched for NP-C.
The NP-C Suspicion Index (SI; http://www.npc-si.com)
is an online clinical screening tool that was developed to
help identify patients who may require further in-depth
laboratory investigation for NP-C [15]. However, the dis-
criminatory performance of the NP-C SI in patient groups
with high levels of NPC-compatible disease features, in
particular those with EOA, has been questioned [3, 10].
Here, we conducted a large retrospective cohort study
aiming to determine whether: (1) the previously established
NP-C SI indeed allows discrimination between EOA
patients with NP-C (NP-C EOA cases) and EOA patients
without NP-C (EOA controls) and (2) a novel abbreviated
‘2/3 SI’ might allow an even more rapid appraisal of sus-
pected NP-C in unexplained EOA.
Methods
Patients
The EOA control group comprised a consecutive series of
86 index patients with early onset degenerative ataxia (age
at onset \40 years) and a family history consistent with
autosomal recessive inheritance (no ataxia in the parental
generation), and who were tested negative for NP-C gene
mutations, recruited between 2006 and 2012. NPC1 and
NPC2 mutations were ruled out as part of a high-coverage
([94 % with a depth C20) custom-built targeted rese-
quencing HaloPlex gene panel (Agilent, Santa Clara, CA,
USA), which included 122 known ataxia genes (see
Synofzik et al. [12] for details).
NP-C EOA cases comprised a multicentre cohort of
patients assessed in five centres in Europe and Australia
between July 2010 and January 2011, who had EOA (i.e.
degenerative ataxia with age of onset \40 years) and
confirmed NP-C diagnosed in the clinical practice setting
based on filipin staining as well as NPC1/NPC2 mutation
analysis. All patients included in this analysis were aged
[4 years.
Assessments
Clinical signs and symptoms were evaluated by retro-
spective chart review in NP-C EOA cases and EOA con-
trols by systematic phenotyping according to the standard
SI protocol [15]. For reasons of simplicity and conformity,
we continued to use the term ‘vertical supranuclear gaze
palsy (VSGP)’ from this SI protocol, although this type of
central oculomotor disorder is more appropriately descri-
bed as ‘vertical supranuclear saccade palsy’. The dis-
criminatory performance of the NP-C SI was subsequently
compared in these two patient groups based on calculated
SI risk prediction scores (RPS), with appropriate sensitivity
and specificity analyses.
To provide a very brief tool for rapid clinical appraisal,
analyses were conducted to investigate a new, simplified
version of the original SI. Sensitivity/specificity analyses
were performed based on univariable logistic regression for
19 signs and symptoms plus the ‘sibling with NP-C or
cousin with NP-C’ item included in the original SI tool
[15]. The three signs and symptoms that provided the
greatest sensitivity and specificity were selected for the
development of a ‘2/3’ SI model, which attributed one
point for the presence of each of the three key manifesta-
tions in combination with ataxia.
Data analysis
Patient demographics, disease manifestations and RPS
scores were summarised using descriptive statistics.
Between-group statistical comparisons of descriptive data
on demographics and disease manifestations in NP-C EOA
cases and EOA controls were conducted using the Wil-
coxon Mann–Whitney for continuous data, and Chi-square
or Fisher’s exact tests where applicable for categorical
data.
For assessment of both the original SI and the new 2/3
SI tool in all ataxic patients, the relationship between the
calculated RPS and the likelihood of NP-C was modelled
using univariable logistic regression (ULR) as described
previously [15]. Logistic regression modelling was per-
formed using Proc Logistic in SAS version 9.3.
Discriminatory performance was assessed based on
receiver operating characteristic (ROC) curves and subse-
quent area under the curve (AUC) analyses. Sensitivity and
specificity values were plotted versus total RPS and tabu-
lated at fine RPS intervals to assess the performance for
different cut-offs.




A total of 133 patients were included in the study: 47 NP-C
EOA cases and 86 EOA controls (Table 1). The propor-
tions of female patients in the NP-C EOA case and EOA
control groups were similar (49 and 44 %, respectively).
The mean (SD; range) age of NP-C EOA cases was lower
[24 (13) years; 4–52] than that in the EOA control group
[31 (12) years; 7–62].
In the EOA control group, 35/86 (41 %) of the index
EOA cases remained genetically unexplained after
screening for the panel of 122 known ataxia-related gene
mutations, while a molecular diagnosis for causal ataxia
gene mutations was established in 51/86 (59 %) cases
(Supplementary Table 1).
Signs and symptoms: descriptive data
The frequencies of NP-C signs and symptoms included in
the original NP-C SI tool [15] in both EOA groups are
summarised in Fig. 1. Among neurological manifestations,
VSGP, cognitive decline/dementia and dysarthria/dyspha-
gia were all recorded in association with ataxia in[80 %
of NP-C EOA cases. Among EOA controls, the most
common neurological manifestations (observed in[50 %
patients) were dysarthria/dysphagia (in 87 % patients) and
spasticity (in 58 %).
Descriptive data analysis allowed identification of the
most frequent NP-C disease manifestations that occurred
substantially more frequently in NP-C EOA cases com-
pared with EOA controls, and which could therefore
potentially serve as differentiating features between these
two specific patient groups. These included VSGP (in 94 %
of NP-C EOA cases versus 8 % of EOA controls;
p\ 0.001), cognitive decline and/or dementia (94 versus
23 %, respectively; p\ 0.001), splenomegaly (47 versus
0 %; p\ 0.001), dystonia (49 versus 5 %; p\ 0.001), any
psychotic signs other than cognitive decline/dementia
(6–30 versus 7 %; p values 0.101 to\0.001), and seizures
(28 versus 8 %; p = 0.004).
Notably, dysarthria/dysphagia and delayed develop-
mental milestones occurred in similar proportions of
patients in the two patient groups. ‘Acquired and progres-
sive spasticity’ was more common in the general EOA
population compared with NP-C EOA cases (58 versus
32 %, respectively; p = 0.006).
Assessment of original NP-C SI performance
Findings from the descriptive analysis of the proportions of
patients with low (0–39 points), moderate (40–69 points) or
high (C70 points) RPS are summarised in Fig. 2. A
notable number of EOA control patients had a moderate
[n = 16/86 (19 %)] or high [n = 8/86 (9 %)] RPS. How-
ever, the scores of the NP-C EOA cases were significantly
higher (p\ 0.001, Fisher’s exact test), and most of them
had a high RPS [46/47 (98 %)].
Figure 3 illustrates findings from the analysis of RPS
sensitivity and specificity in NP-C EOA cases versus EOA
controls. Predictably, specificity increased and sensitivity
decreased as total RPS rose. The cut-off RPS of 40 (for
moderate suspicion) provided a sensitivity of 100 % and a
specificity of 70 %. The cut-off RPS of 70 (for high sus-
picion) provided a sensitivity of 98 % and a specificity of
91 %.
Univariable linear regression modelling and ROC
analysis of RPS revealed an AUC of 0.982 in NP-C EOA
cases versus EOA controls (Supplementary Fig. S1), which
compares well with findings from a post hoc subgroup
analysis for patients aged C4 years who were included in
the original SI development study (AUC 0.997) [15].
The discriminatory performance of the NP-C SI
appeared unaffected by patient age (Fig. 4). Area under the
curve values for subgroups of patients aged [4, [10 and
[18 years were 0.982, 0.980 and 0.977, respectively,
indicating excellent performance across all age groups.
Assessment of 2/3 SI performance
Given that clinical routine often requires very rapid and
efficient bedside testing, we evaluated a shorter form of the
NP-C SI that required assessment of only three clinical
Table 1 Patient demographics
NP-C EOA cases (N = 47) EOA controls (N = 86)
Gender, n (%) femalea 23 (49) 38 (44)
Age (years)b
Mean (SD) age 24 (13) 31 (12)
Median (range) 21 (4–52) 32 (7–62)
Statistical comparisons (NP-C vs. non-NP-C EOA cases)
a Chi-square test, p = 0.599
b Wilcoxon-Mann–Whitney test, p = 0.001
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features, called the ‘2 out of 3’ tool (‘2/3’ SI). From the
panel of 21 original SI items, VSGP, pre-senile cognitive
decline and/or dementia, dystonia, and splenomegaly were
identified as those with the greatest sensitivity and speci-
ficity for the detection of NP-C (Table 2). For the 2/3 SI
only the first three features were selected (VSGP, pre-se-
nile cognitive decline and/or dementia, and dystonia).
We observed a clear difference in the distribution of 2/3
SI scores between NP-C EOA cases and EOA controls
(Fig. 5). In total, 90 % of NP-C EOA cases had 2/3 SI
scores of 2 or 3. In contrast, 90 % of EOA controls had
scores of 0 or 1 on this tool. Based on ROC analyses, the
2/3 SI tool was effective at discriminating NP-C EOA
cases from EOA controls, providing an AUC of 0.961 in
NP-C EOA cases versus EOA controls, which is compa-
rable with the excellent value achieved with the original SI
tool in this ataxia cohort.
From sensitivity and specificity analyses at different 2/3
SI score levels, a score of 1 point (indicating moderate
suspicion) provided a sensitivity of 100 % and a specificity
of 73 %, and a score of 2 points (indicating high suspicion)
provided a sensitivity of 89 % and a specificity of 91 %. A
score of 3 points provided 100 % specificity: sensitivity at
this level was relatively low (47 %).
Post hoc statistical testing, taking 2 points on the 2/3
tool and a score of 70 on the original SI as cut-off values
indicating high suspicion of NP-C, indicated that the
original SI had the greatest overall sensitivity (0.89 versus
0.98; p = 0.0078).
Subgroup analysis excluding VSGP and Friedreich’s
ataxia
We conducted subgroup analyses to assess the effect of
absent VSGP on original SI and 2/3 SI performance, and
the influence of Friedreich’s ataxia (FRDA) on the sensi-
tivity and specificity of both SI scores. Predictably, the
absence of VSGP rendered the 2/3 SI substantially less
sensitive for the detection of NP-C, while the sensitivity of
the original SI was relatively unaffected (Supplementary
Fig. S2). The preponderance of FRDA in our cohort had no
influence on the observed sensitivity or specificity of either
the original SI or the 2/3 SI (Supplementary Fig. S2).
Discussion
A large proportion of adult NP-C patients still remain
undiagnosed in clinical practice [14]. The clinical recog-
nition of NP-C is still affected by levels of awareness of the
disease, and on the ability of diagnosing physicians to
recognise suggestive signs and symptoms. The NP-C SI
can aid in establishing a vital diagnostic link between
clinical observations and eventual laboratory confirmation.
However, while this tool is known to be effective in dis-
tinguishing NP-C patients from the general population
[15], its ability to distinguish between NP-C cases and
other multisystemic neurologic diseases with a high load of
NPC-compatible disease features—such as EOA—has
Fig. 1 Symptom frequency in
NP-C EOA cases versus EOA
controls
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been questioned [4, 10]. Further, the identification of a
clinical bedside tool that allows rapid appraisal of NP-C
suspicion is of particular importance for EOA, as patients
with this condition have been shown to represent a high-
risk group for NP-C [12].
Excellent discriminatory performance in distinguishing
EOA NP-C cases from EOA controls was observed with
both the original NP-C SI and the novel 2/3 SI tool. The
latter is easier to remember and quicker to apply than the
original NP-C SI, and yet does not lose any discriminatory
power. Based on the current findings we would recommend
that, for the practical application of these SI tools, genetic
testing for NP-C mutations should be considered advisable
at thresholds of C70 points for the original SI and 2 or 3
points for the 2/3 tool.
Importantly, the EOA control group used for compara-
tive reference with the NP-C EOA case group in this study
comprised a wide range of EOA aetiologies, with inci-
dences similar to those generally encountered in clinical
practice [2, 5]. The proportion of patients in whom
molecular diagnoses based on causal ataxia gene mutations
were established (59 %) was similar to findings from pre-
vious studies in both European cohorts (55 %) [2] and
high-consanguinity non-European cohorts (66 %) [5].
Further, as in the general EOA population [2], FRDA
represented the bulk of genetically confirmed EOA cases
(59 % of all genetically solved EOA cases) in our EOA
control cohort. Subgroup analysis excluding FRDA
patients showed equally good discriminatory performance
of both original and 2/3 NP-C SI scores among complex
non-FRDA EOA patients, where differential diagnosis is
particularly complicated.
The notable numbers (approximately one-third) of EOA
controls with moderate-to-high scores on the original NP-C
SI confirm that EOA indeed has a high ‘background level’
of broadly NPC-compatible multisystemic disease features
[3, 10]. All of the molecular EOA diagnoses identified
among our EOA controls (see Supplementary Table 1) are
known to present with a substantial extra-cerebellar disease
load. This placed a high burden on the NPC-SI to provide
Fig. 2 Proportions of NP-C EOA cases and EOA controls with low,
moderate and high RPS on the original NP-C SI
Fig. 3 Sensitivity-specificity analysis for NP-C SI RPS in NP-C
EOA cases versus EOA controls. Dashed vertical lines represent cut-
off values for moderate (40) and high risk (70) of NP-C
Fig. 4 Total NP-C SI risk prediction scores by patient age
J Neurol (2016) 263:1911–1918 1915
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sufficient discriminatory power to distinguish the NP-C
cases.
Modelling assessments identified the top discrimina-
tory features from the original SI tool for NP-C, from
which VSGP, pre-senile cognitive decline and/or
dementia, and dystonia were selected for incorporation
into the 2/3 SI tool. The fact that VSGP and cognitive
decline/dementia in particular were all recorded in
[80 % of NP-C EOA cases confirms and extends find-
ings from an earlier study [10]. Although splenomegaly
yielded degrees of sensitivity and specificity for NP-C
cases similar to that of dystonia, it was not selected for
the 2/3 SI tool because it is frequently overlooked in
clinical practice, is often mild or even absent in adult-
onset cases [11], and is not always easy to evaluate on a
mere clinical basis. Acquired and progressive spasticity
was not selected based on its relatively low sensitivity
and specificity, demonstrating that it is a frequent feature
across many EOAs of different aetiologies [4].
Several limitations apply to this study. Firstly, our
findings on the excellent discriminatory power of both the
original and 2/3 NP-C SI in EOA are limited by the ret-
rospective study design, which engender potential bias.
Prospective studies are highly warranted to confirm the
current findings. The 2/3 SI tool also requires further,
independent validation in unrelated EOA cohorts. Other
prospective studies will also help address the discrimina-
tory power of the both SI tools in other patient populations
with characteristic NP-C features, such as those with early
onset cognitive decline or signs of organic, treatment-re-
sistant psychosis.
All patients in this analysis were[4 years old. Previous
studies have demonstrated that the discriminatory perfor-
mance of the original NP-C SI is the greatest in non-in-
fantile patients [6, 17]. Nevertheless, regression analysis in
the current study to identify any relationship between
patient age and original NP-C SI scores demonstrated the
ability of this tool to distinguish between NP-C EOA and
non-NP-C EOA across all patients aged[4 years. It should
also be noted that the 2/3 SI is unlikely to be helpful in
early infantile patients or neonates. While VSGP is a
common neurological finding in patients with NP-C, par-
ticularly among those with juvenile- or adolescent/adult-
onset neurological symptoms, it is less frequent among
infantile-onset patients who are more commonly charac-
terised by visceral manifestations. Our subgroup analyses
revealed that the absence of VSGP rendered the 2/3 SI
substantially less sensitive for the detection of NP-C: the
sensitivity of the original SI was relatively unaffected.
Published data indicate that the occurrence of VSGP is
Table 2 Findings from
sensitivity and specificity
analyses of the five NP-C SI key
signs and symptoms providing
the best performance based on
co-occurrence with ataxia
Manifestation Sensitivity Specificity
VSGP (%) 94 92
Pre-senile cognitive decline and/or dementia (%) 94 77
Dystonia (%) 49 95
Isolated unexplained splenomegaly ± hepatomegaly (%) 47 100
Acquired and progressive spasticity (%) 32 42
Prolonged unexplained neonatal jaundice or cholestasis (%) 17 100
Hydrops foetalis ND ND
Siblings with foetal ascites ND ND
Gelastic cataplexy (%) 19 100
Dysarthria and/or dysphagia (%) 83 13
Hypotonia (%) 2 100
Delayed developmental milestones (%) 30 81
Seizure (partial or generalised) (%) 28 92
Myoclonus (%) 11 95
Acquired and progressive spasticity (%) 32 42
Psychotic symptoms (%)a 30 95
Treatment-resistant psychiatric disorders (%) 19 86
Disruptive/aggressive behaviour in adolescence and childhood (%) 6 100
Other psychiatric disorders (%) 19 93
Parent or sibling with NP-C (%) 13 100
Cousin with NP-C (%) 2 100
ND not determined (none of the EOA subjects had the sign or symptom)
a Hallucinations, delusions and/or thought disorder
1916 J Neurol (2016) 263:1911–1918
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highly correlated with that of ataxia in NP-C [17], so if
VSGP is not present it is likely that a patient would also not
exhibit discernible ataxia, which would render the 2/3 even
less effective. For these reasons, a separate SI tool targeted
towards use in infantile patients is currently under devel-
opment: initial findings from a total of 200 patients (106
NP-C infants and 94 non cases and controls) indicate
improved discriminatory performance compared with the
original SI [7].
Finally, while this study demonstrated that both the
new 2/3 tool and the original SI provided equivalent
areas under the ROC curve (both [0.95) and were
effective in distinguishing between NP-C and non-NP-C
EOA patients, the original NP-C SI demonstrated the
greatest overall sensitivity compared with the 2/3 tool.
Given the low prevalence of NP-C, as a rare disease, this
might lead some clinicians to choose the original NP-C
SI in preference to the 2/3 tool, despite the obvious
advantages of the 2/3 tool in terms of rapidity and
convenience.
Conclusion
In conclusion, this study showed that the original SI has an
excellent discriminatory performance even in multisys-
temic neurologic diseases with a high load of NPC-com-
patible disease features like EOA. In addition, the much
simpler and more rapidly applicable 2/3 SI tool showed
similar sensitivity and specificity to the original SI, and
might serve as a more easily applicable tool for bedside
assessment. While we would recommend application of the
original SI in patients who do not have VSGP, the abbre-
viated 2/3 tool would seem ideally suited for initial bedside
evaluations for NP-C and should also prove useful in
broader screening studies in EOA patients.
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